Investigation of Amyloid β Oligomer Dissociation Mechanisms by Single Molecule Fluorescence Techniques by Abdalla, Hope Cook
University of Kentucky 
UKnowledge 
Theses and Dissertations--Chemistry Chemistry 
2019 
Investigation of Amyloid β Oligomer Dissociation Mechanisms by 
Single Molecule Fluorescence Techniques 
Hope Cook Abdalla 
University of Kentucky, ehco224@uky.edu 
Digital Object Identifier: https://doi.org/10.13023/etd.2019.018 
Right click to open a feedback form in a new tab to let us know how this document benefits you. 
Recommended Citation 
Abdalla, Hope Cook, "Investigation of Amyloid β Oligomer Dissociation Mechanisms by Single Molecule 
Fluorescence Techniques" (2019). Theses and Dissertations--Chemistry. 109. 
https://uknowledge.uky.edu/chemistry_etds/109 
This Master's Thesis is brought to you for free and open access by the Chemistry at UKnowledge. It has been 
accepted for inclusion in Theses and Dissertations--Chemistry by an authorized administrator of UKnowledge. For 
more information, please contact UKnowledge@lsv.uky.edu. 
STUDENT AGREEMENT: 
I represent that my thesis or dissertation and abstract are my original work. Proper attribution 
has been given to all outside sources. I understand that I am solely responsible for obtaining 
any needed copyright permissions. I have obtained needed written permission statement(s) 
from the owner(s) of each third-party copyrighted matter to be included in my work, allowing 
electronic distribution (if such use is not permitted by the fair use doctrine) which will be 
submitted to UKnowledge as Additional File. 
I hereby grant to The University of Kentucky and its agents the irrevocable, non-exclusive, and 
royalty-free license to archive and make accessible my work in whole or in part in all forms of 
media, now or hereafter known. I agree that the document mentioned above may be made 
available immediately for worldwide access unless an embargo applies. 
I retain all other ownership rights to the copyright of my work. I also retain the right to use in 
future works (such as articles or books) all or part of my work. I understand that I am free to 
register the copyright to my work. 
REVIEW, APPROVAL AND ACCEPTANCE 
The document mentioned above has been reviewed and accepted by the student’s advisor, on 
behalf of the advisory committee, and by the Director of Graduate Studies (DGS), on behalf of 
the program; we verify that this is the final, approved version of the student’s thesis including all 
changes required by the advisory committee. The undersigned agree to abide by the statements 
above. 
Hope Cook Abdalla, Student 
Dr. Jason DeRouchey, Major Professor 
Dr. Mark Lovell, Director of Graduate Studies 
Investigation of Amyloid β Oligomer Dissociation Mechanisms by Single Molecule 
Fluorescence Techniques 
______________________________ 
THESIS 
________________________________________ 
A thesis submitted in partial fulfillment of the 
requirements for the degree of Master of Science in the 
College of Arts and Sciences  
at the University of Kentucky 
By 
Hope Cook Abdalla 
Lexington, Kentucky 
Director: Dr. Jason DeRouchey, Professor of Chemistry 
Lexington, Kentucky 
2018 
Copyright © Hope Cook Abdalla 2018 
ABSTRACT OF THESIS 
Investigation of Amyloid β Oligomer Dissociation Mechanisms by Single Molecule 
Fluorescence Techniques 
Alzheimer’s disease (AD) is currently considered the most prevalent 
neurodegenerative disease and places a large financial burden on society as healthcare 
resources are limited and the disease does not have a cure. Alzheimer’s disease is 
characterized by the presence of amyloid beta (Aβ) plaques and neurofibrillary tangles; 
however current literature suggests Aβ oligomers are the main aggregating species leading 
to AD symptoms. Therefore, the underlying cause of Alzheimer’s, accumulation of 
amyloid beta, is currently being studied in hopes of developing treatment options. Our 
research aims at determining the mechanism and kinetics of Aβ oligomer dissociation into 
non-toxic monomers in the presence of denaturants or small molecule dissociators. These 
highly active small molecule dissociators, selected from the Apex Screen 5040 library, 
were previously identified by ELISA studies by the laboratory of Dr. Harry LeVine. We 
have used fluorescence correlation spectroscopy (FCS) to characterize the size distribution 
and mole fraction of synthetically prepared fluorescein labeled Aβ (1-42) oligomers. Our 
FCS results show that in the presence of denaturants or small molecule dissociators, 
oligomer dissociation may proceed by at least two different mechanisms; high order 
cooperative dissociation and linear dissociation. A cooperative mechanism is more 
desirable for therapeutics as oligomer directly dissociates into monomer rather than 
through various oligomer intermediates. Our FCS studies show the most efficient 
dissociators proceed through the cooperative dissociation mechanism. We also observed a 
large retardation of the oligomer dissociation in the presence of gallic acid. We also started 
preliminary work to develop a total internal reflection fluorescence (TIRF) spectroscopy 
method to image Aβ (1-42) oligomers. This technique if successful will help to verify the 
two distinct mechanisms seen by FCS or determine if there is one mechanism that occurs 
at different rates as TIRF allows for faster analysis.   
KEYWORDS: Alzheimer’s disease, Amyloid β, oligomer dissociators, fluorescence 
correlation spectroscopy, total internal reflection fluorescence 
spectroscopy, dissociation mechanisms. 
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Chapter 1: Introduction 
1.1 What is Alzheimer’s disease?  
Alzheimer’s disease (AD) is the most prevalent slowly progressing irreversible 
neurodegenerative disease and the sixth leading cause of death in the US.1 This disease 
greatly affects the patient’s daily life due to symptoms such as memory loss, depression, 
disorientation, confusion, behavior changes, poor judgement, and loss of motor functions. 
Furthermore, Alzheimer’s places a huge economic burden on society as an individual 
with Alzheimer’s cannot care for themselves and there is currently no cure for the 
disease. The main risk factor for AD is advanced age therefore, as life expectancy 
increases the economic burden also increases. In fact according to the annual Alzheimer’s 
association report more than five million Americans currently have this disease and this 
number continues to rise annually.1 For therapeutics to be developed we must understand 
the complex pathology of this disease.  
Alzheimer’s is characterized by two main pathologies, amyloid beta plaques and 
neurofibrillary tangles, which begin to form within the brain about twenty years before 
the onset of symptoms. While the formation of these pathologies begins in the 
hippocampus, where memories are stored, the neuron damage spreads throughout the 
brain, as shown in Figure 1.1, over time leading to severe brain atrophy.  
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Figure 1.1 Alzheimer’s disease leads to neuron death and brain atrophy. Reprinted from 
reference: 2017 Alzheimer's Disease Facts and Figures Alzheimer's Association: 
Alzheimers Dement, 2017; pp 325-373. 
It is important to understand that the two pathologies are very different; while 
amyloid beta plaques are formed by aggregated amyloid beta peptide; neurofibrillary 
tangles, are composed of tau protein.  As shown in Figure 1.2, these neurofibrillary 
tangles form when tau becomes hyperphosphorylated causing tau to fall off the 
microtubule, the track for intracellular trafficking of components, thereby destabilizing 
the microtubule. Once the microtubule falls apart transport of vital components cannot 
occur thereby leading to neuron death.  
On the other hand, excess amyloid beta results from the loss of equilibrium of 
amyloidogenic pathway due to excess β-secretase either causing overproduction or 
impaired degradation of amyloid β. Therefore, the excess amyloid beta cannot be cleared 
by the neuron leading to aggregated amyloid beta peptides which block synaptic neuron 
signaling by binding to synaptic receptors or to the neuron cell membrane leading to 
neuron death.  
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While both tau and amyloid β play an important role in AD pathology, our focus 
is on Aβ oligomers as recent studies have shown that Aβ accumulation acts as the trigger 
for tau.2 To back this claim, a recent study by Stancu et.al showed that mice with both 
amyloid and tau pathology had more hippocampal atrophy than mice with only tau. 
Furthermore, amyloid pathology was not affected or accelerated by the presence of tau.2 
Aβ oligomers are able to activate tau pathology by binding to receptors inhibiting normal 
function, this will be discussed in more detail later in this thesis.  
Figure 1.2 The two main AD pathologies leading to neuronal death. 
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1.2 Alzheimer’s disease stages 
It is understood, thanks to the search for Alzheimer’s biomarkers that the 
progression of Alzheimer’s disease is divided by three contiguous stages: the preclinical 
stage (PCAD), mild cognitive impairment (MCI) and late stage Alzheimer’s disease 
(LAD). Furthermore, these stages are often associated with the Braak scoring system for 
neurofibrillary tau pathology in AD ; given a score from 0 to VI which correlates to the 
amount of neurodegeneration and memory loss, Figure 1.3.3-4 The preclinical stage 
correlates to a I to II on the  Braak scale and can last 10 years or more. During PCAD 
there are no clinical signs of Alzheimer’s disease, however there are signs of neuronal 
degeneration. Therefore, the preclinical stage is currently known as the earliest detectable 
pathological phase. While this stage is not a diagnostic stage as not all patients reach the 
dementia state; it is important to understand to develop therapeutics. The mild cognitive 
impairment state is characterized by III to IV on the Braak scale and an increased 
presence of Aβ plaques and neurofibrillary tangles as well as cognitive decline faster than 
expected given a patient’s age. However, the symptoms unlike LAD, do not dramatically 
interfere with the patient’s everyday life. 5 The last stage of LAD is known to be a V to 
VI on the Braak scale and is characterized by neurodegeneration in many parts of the 
brain and severe cognitive decline. 3  
5 
Figure 1.3 Braak staging scale, areas affected by Aβ plaques are highlighted in red. 
Reprinted from reference: Ovsepian, S. V., and O’Leary, V.B. Neuronal Activity and 
Amyloid Plaque Pathology: An Update. Journal of Alzheimer’s Disease 2016, 49, 13-19. 
1.3 History of Alzheimer’s disease discovery 
Alzheimer’s disease (AD) was first described by German physician Dr. Alois 
Alzheimer in 1901 when 51-year-old patient Auguste Deter, was observed for severe 
memory loss and erratic behavior.6 When Auguste passed away, in 1906, Alzheimer 
discovered lesions in the brain that caused significant neuronal shrinkage around neurons 
via autopsy.6 While Alzheimer was the first to connect the symptoms of the disease with 
the pathology Alzheimer did not name the disease. Interestingly, the term was coined in 
1910 by German psychiatrist Emil Kraepelin7.  The abnormal deposits, however, were 
not fully characterized until 1984 when Glenner and Wong purified a 4.2 kDa protein 
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from β rich fibrils found in AD brain. They named this protein amyloid beta (Aβ). 8-9 
Glenner and Wong also noticed that Down’s syndrome patients cognitively decline by 
age 40 and hypothesized this was due to a connection to AD. Their hypothesis was that a 
gene on chromosome 21, which is the chromosome in excess in Down’s, codes for 
amyloid precursor protein (APP) which they believed undergoes proteolysis to form 
amyloid beta. After autopsying brains of Alzheimer’s patients and Down’s patients they 
saw the same pathology of amyloid plaques and neurofibrillary tangles in both cases 
proving Down’s patients develop AD.10  Then in 1986, researchers discovered another 
key protein to AD, tau protein and proposed that hyperphosphorylated tau falling off 
assembled microtubules leads to neurofibrillary tangles which could be another main 
suspect for causing Alzheimer’s.11 
Alzheimer’s was further linked to APP in 1990 when an APP mutation, changing 
glutamic acid to glutamine at codon 693 was discovered in severe cases of cerebral 
hemorrhage with amyloidosis. This mutation disrupted the proteolytic processing of APP 
increasing Aβ deposits.12-13 After this discovery three more missense mutations were 
discovered in APP at codon 717 which changes valine to isoleucine, phenylalanine or 
glycine which also disrupt the proteolysis.13 Lastly the discovery of another mutation 
affecting APP proteolysis in familial Alzheimer’s involving presenilins 1 and 2 furthered 
the understanding of how APP leads to Aβ.12  The amyloid cascade hypothesis, coined by 
John Hardy in 1992, combined all these findings stating that Aβ, a product of APP 
proteolysis, is the main causative agent of Alzheimer’s pathology leading to plaques and 
then neurofibrillary tangles and neuronal death.13 This has been the widely accepted 
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mechanism of Alzheimer’s disease since the 1990s and is described in the following 
section.  
1.4 Amyloid Cascade hypothesis 
Before Aβ oligomers form, the amyloid precursor protein (APP), a type I integral 
glycoprotein localized at the synapse, plasma membrane, endoplasmic reticulum (ER), 
Golgi apparatus, endosomes, lysosomes, and mitochondria, must undergo proteolytic 
cleavage.14  Even though the holo-APP protein has been shown to be neuroprotective 
involved in neuronal cell growth, neuron to neuron communication and synaptic 
plasticity; two very different pathways of APP processing exist: one normal 
(nonamyloidogenic) and the other toxic (amyloidogenic) and proceed as shown in Figure 
1.4.15 
 In the nonamyloidogenic pathway APP cleavage is catalyzed by α secretase 
(present in the Golgi or at plasma membrane) which cleaves the APP to form the 
membrane anchored fragment C83 (C-terminal APP with 83 amino acids) and sAβPPα
(soluble N-terminal APPα). C83 is then cleaved by  secretase (multimeric complex of 
presenilin proteins) to form the amyloid precursor protein intracellular domain (AICD) 
and extracellular P3 peptide (residues 17-40/42), which cannot form stable oligomers as 
N-terminal residues 1-16 present in Aβ oligomers are absent in P3. Therefore, the
hydrophobic core is less protected, and the hydrophobic residues are exposed which 
results in P3 being less stable than Aβ oligomers. Furthermore, sAβPPα levels are reduced 
in AD patients and higher levels are found to have many benefits such as calcium 
regulation and prevention of neurotoxic Aβ buildup.14  
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On the other hand, in the amyloidogenic pathway, APP is first cleaved by β 
secretase (BACE I, present in Golgi or endosomes) and then  secretase.  When APP is 
first cleaved by BACE a C99 peptide (C terminal APP with 99 amino acids) and sAβPPβ 
(soluble N-terminal APPβ) are produced. Then C99 is cleaved by  secretase to form 
AICD along with extracellular Aβ (1-40) and Aβ (1-42). Aβ then aggregates into 
oligomers before forming plaques. Therefore, BACE is considered the rate limiting 
enzyme in oligomer production as it is required for plaque formation and Aβ is 
prefentially made in the Golgi as BACE is located there. However, two receptors called 
SorLA (neuron sorting receptor) and LRP1B (low density lipoprotein receptor related 
protein B) receptor counteract this process by sequestering the APP at the membrane to 
block BACE, but these receptors are reduced in Alzheimer’s.14 
Figure 1.4:  APP cleavage pathways. The non- amyloidogenic pathway is nontoxic as Aβ 
is not formed while the amyloidogenic pathway is toxic.  
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 1.5 Amyloid beta assembly 
Amyloid beta peptide assembly exists in multiple forms which include monomer, 
paranuclei, oligomer, protofibrils and fibrils, shown in Figure 1.4. While amyloid beta 
assembly of monomer to oligomer is reversible the process is kinetically slow and not 
well understood.16 Moreover, α helical monomer is neuroprotective but tends to self-
assemble into neurotoxic oligomers. Since oligomers lack stable tertiary structure, they 
spontaneously change conformation forming a more stable form called protofibrils. 
Protofibrils look like beads on a string and are an intermediate of fibrils lacking a defined 
β motif.17 Protofibrils then continue to spontaneously assemble into well-defined β sheet 
rich fibrils ultimately leading to the hallmark amyloid beta plaques of AD. 
 It is important to note that there are two different main isoforms of Aβ seen in 
AD: Aβ (1-40) and Aβ (1-42), which are 40 and 42 amino acids long respectively. While 
the Aβ (1-42) only differs by two extra hydrophobic C terminus residues; the two 
isoforms have very different biological behavior.  Our studies focus on the Aβ (1-42) 
isoform as it more commonly seen in plaques associated in AD.18 However, the distinct 
differences between the assembly pathways of the two isoforms is important to 
understand as these differences may explain why Aβ (1-42) levels are higher.19 While Aβ 
(1-40) does form fibrils the rate of fibril formation is slower as the less hydrophobic  Aβ 
(1-40) is more stable. Furthermore, Aβ(1-40) more commonly exists as a mixture of 
monomer, dimer, trimer, and tetramer in equilibrium, while Aβ (1-42) prefers to form 
pentamer and hexamer units, called paranuclei, Figure 1.5.19  The paranuclei then self-
assemble to larger oligomers which  leads to faster fibril formation. The formation of the 
paranuclei has been linked to the 2 extra hydrophobic residues in Aβ (1-41); Bitan, et.al 
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showed the 41 residue Ile sec-butyl side-chain and the 42 residue Ala methyl sidechain to 
be necessary for paranuclei formation and self-association.19 
Figure 1.5: Amyloid beta (1-42) assembly pathway. Monomers spontaneously assemble 
into paranuclei which self-assemble into oligomers which then form protofibrils before 
forming fibrils. 
1.6 Amyloid beta oligomer toxicity 
While amyloid plaques formed from Aβ fibrils used to be considered as the main 
toxic species in AD, it is now understood that these plaques also contain Aβ oligomers 
which are the toxic component of plaques; thereby shifting the focus off of plaques.8, 20 
Furthermore, unlike oligomers, plaques do not necessarily correlate with memory loss 
and removing plaques does not stop or reverse AD progression.21 In fact several animal 
studies show that oligomers injected into the brain cause decreased synaptic plasticity 
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impairing memory while fibrils and monomers do not have a significant effect; further 
supporting oligomer as the toxic agent of AD.22  While the exact mechanism of Aβ 
toxicity is still unclear the one thing that everyone can agree on is that toxicity is related 
to the dysfunction of a mixture of processes related to Aβ oligomer accumulation.23  
Oligomers interact with the neuron in one of two ways depending on the 
oligomer’s size, as seen in Figure 1.6. While large oligomers (over 50 kDa) tend to bind 
receptors; small oligomers (less than 50 kDa) tend to bind cell membrane on regions rich 
in phosphatidylserine (PtdSer), cholesterol, or lipid rafts, causing the lipid bilayer to thin 
resulting in pore formation and ion dishomeostasis.24  
Figure 1.6: The main toxic species in AD are oligomers. While smaller oligomers cause 
neuron death by forming pores in the neurotic membrane; larger oligomers bind to 
synaptic receptors. 
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Our research focuses on large oligomers that lead to synaptic dysfunction and 
excitotoxicity by activating signaling cascades after binding to the synaptic receptors.  
Processes that are affected by oligomers binding receptors include ion homeostasis, tau 
phosphorylation, the cell cycle, axonal transport, insulin signaling, ER processing, 
proteasome function, mitochondrial function, autophagy, and oxidation inhibition all 
leading to apoptosis of neurons. Moreover, Aβ oligomers can target multiple receptors to 
inhibit these biological processes including APOE/LRP1, RAGE, Frizzled, NMDA, α-7 
nicotinic acetylcholine (α7nAChR), glutamate, insulin, LilrB2, EphB2, and prion protein 
PrPC receptors, as seen in Figure 1.7.  However, oligomers have higher affinity for 
EphB2, glutamate, NMDA, and PrPC receptors which are concentrated on dendrites 
suggesting  oligomers prefer to bind dendrites over axons and due to this 
neurotransmission is lost leading to synaptic dysfunction and neuron death.25    
When oligomers bind NMDA (N-methyl-D-aspartate) and other glutamate 
receptors, this binding event causes disruption of calcium signaling, decreased 
kinase/phosphatase activity, and increased oxidative stress as levels of reactive oxygen 
species increase. Glutamate excitotoxicity then occurs due to excess glutamate being 
produced leading to decreased processing of glutamate to glutamine as glutamine 
synthetase cannot keep up.26 Furthermore, levels of inhibitory neurotransmitter GABA 
decrease as well, causing more excitotoxicity.26 Excitotoxicity eventually causes voltage 
gated calcium channels to open causing calcium to first flood into the ER, but as levels 
continue to rise, the calcium is then taken up by the mitochondria.27 When calcium levels 
become more than the mitochondria can handle, the mitochondria permeability transition 
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pore opens leading to mitochondrial apoptosis.27 This leads to synaptic dysfunction, 
decreased synaptic plasticity, and neuronal apoptosis as the neuron is starved for ATP. 21, 
28-29 Furthermore, lower levels of ATP have been shown to increase BACE levels, which
as mentioned in section 1.4 is the rate limiting step in Aβ production.30 
Aβ binding nAChR leads to decreased acetylcholine (ACh) production due to 
leakage of choline across the cell membrane leading to increased oligomer accumulation 
and internalization.15, 21  Increased transport of oligomers into the neurons also occurs 
when oligomers interact with RAGE (receptor for advanced glycation products) leading 
to oxidative stress.15  
When oligomers interact with APOE/ LRP1 (low density lipoprotein receptor 
related protein) Aβ uptake by neurons is increased due to an increase in the rate at which 
BACE binds APP.23  Furthermore, the presence of  APOE-ε4  gene was discovered on 
chromosome 19 which causes APOE to become overexpressed; therefore, individuals 
with this overexpression have an increased risk of getting AD.31 
Aβ oligomers binding to Frizzled receptors lead to inhibition of the Wnt 
(glycoprotein that mediates cell communication, cell movement, polarity, axon guidance, 
and synapse formation) this leads to tau hyperphosphorylation causing neurofibrillary 
tangles and cell death.23  Lastly, when oligomers bind insulin receptors insulin signal 
transduction is impaired causing decreased insulin production, increased oligomer 
production, and decreased oligomer clearance thereby further reducing insulin signaling. 
Because of this reduction of insulin signaling, AD is sometimes referred to Type 3 
diabetes.29  
14 
Figure 1.7. Possible oligomer receptor targets. Reprinted from reference: Kayed, R.; 
Lasagna-Reeves, C. A., Molecular mechanisms of amyloid oligomers toxicity. J 
Alzheimers Dis 2013, 33 Suppl 1, S67-78. 
1.7 Recent studies of amyloid beta oligomers using single molecule analysis 
Traditional methods for analyzing amyloid beta assembly and disassembly include 
ThioT binding, SEC (size exclusion chromatography), AUC (ultracentrifugation), native 
and SDS PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis), DLS 
(dynamic light scattering) and ELISA (enzyme linked immunosorbent assay), however 
many of these techniques are problematic as they require concentrations of Aβ that far 
exceed physiological concentrations.16, 32-34 Furthermore, ThT, which was one of the 
earliest ways to study Aβ, is not useful in studying early oligomerization as it only detects 
the presence of β sheet structure in fibrils.35 SDS PAGE is also problematic as detergents, 
such as SDS, can increase or decrease oligomerization.  In SEC, monomer and small 
oligomer interactions with the column matrix could lead to a shift in equilibrium 
therefore large oligomers may dissociate to account for this effect leading to inaccurate 
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determination of oligomer molecular weight.33, 36 Finally, ELISA is problematic as exact 
number and size of oligomers present cannot be determined.37 Since these traditional 
biochemistry techniques have some drawbacks and Aβ is present in pM to nM 
concentrations in the brain research has shifted to single molecule techniques, such as 
fluorescence correlation spectroscopy (FCS).   
One of the first FCS studies done on Aβ polymerization used rhodamine labeled Aβ 
(1-40) to prove polymerization is cooperative as large aggregates proceed fibrils. 
Tjenberg and collaborators saw fibrils forming after 40 minutes and a decrease in size 
occurred to reach an equilibrium state within 2 hours. This study helped to lay the 
foundation for using FCS as a technique to study Aβ polymerization and inhibition.38  
Novo more recently focused on Aβ monomer aggregation to oligomer using FCS. 
They discovered that aggregates of 28-88 monomers form once a critical aggregation 
concentration (cac) is reached, and below the cac the sample remains monomeric. 
Furthermore, their data again showed aggregation of monomer to oligomer is a 
cooperative process. In this model,  the aggregate size stays constant with increasing  
time or concentration of Aβ (1-42), while  only the number of aggregates increases.39 
Another recent study using FCS to study Aβ aggregation observed Aβ (1-42) using a 
five gaussian distribution to measure monomer, oligomer, protofibrils and fibrils 
simultaneously. However, this model does not work well as it is difficult to distinguish 
monomer from small oligomers and large particles tend to form due to aggregation.40 
Another recent study using FCS to monitor Aβ assembly used ARCAM1 as a fluorescent 
probe. Unlike ThT, ARCAM 1 binds small oligomers. They observed that the 
fluorescence intensity increases 8-fold when Aβ is present. While the experiment was 
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successful in determining oligomer assembly, the measured diffusion coefficient (3.4 
μm2/s) proves protofibrils were still present in solution. 35  
While these recent studies of oligomers tend to focus on understanding amyloid beta 
association rather than dissociation; if we are going to stop AD progression we must 
focus on dissociation as well. Very little research to date has looked at the dissociation 
mechanisms. Furthermore, FCS on a mixture of several components is very complex and 
data analysis becomes near impossible. Therefore, we also need a purer sample with only 
two components.    
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Chapter 2: FCS Studies Materials and Methods 
2.1 Introduction 
My research aimed at determining the mechanisms and kinetics of Aβ oligomer 
dissociation and the effects of small molecule modulation by a series of APEX Screen 
5040 compounds selected for by ELISA, by our collaborator Dr. LeVine.41-42  As 
previously mentioned we choose to focus on oligomers because they are the main toxic 
species in AD and tau pathology seen in AD cannot be present without Aβ. While the 
compounds in this study were known dissociators the exact mechanism of dissociation 
was not well defined, as ELISA is unable to accurately detect oligomer size, as 
previously mentioned. By expanding this study to fluorescence correlation spectroscopy, 
FCS, we can overcome these shortcomings of ELISA; as FCS allows us to monitor both 
the hydrodynamic radius (size) and the concentration in real time giving us a glimpse of 
how the molecule is dissociating. Furthermore, FCS allows us to use physiological 
concentration (nanomolar to picomolar) therefore avoiding the increased aggregation of 
Aβ observed at higher concentrations.  
Previous research by the DeRouchey lab has shown that Aβ oligomer dissociation 
proceeds by at least two different mechanisms; high order cooperative dissociation and 
linear or non-cooperative dissociation. The cooperative mechanism is more desirable for 
therapeutics as oligomer directly dissociates into monomer whereas in the linear 
mechanism oligomer size and mole fraction progressively decrease forming oligomer 
intermediates. By continuing our analysis of Aβ dissociation using FCS, we will be able 
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to better understand these two mechanisms as well as probe for the existence of other 
mechanisms.  
2.2. Background of Fluorescence Correlation Spectroscopy 
Fluorescence correlation spectroscopy, FCS, measures fluorescence fluctuations 
of fluorescently labeled molecules as they diffuse through the confocal volume (or the 
observed or in focus volume (femtoliter scale)) by Brownian motion. Since it was first 
developed in the 1970s by Madge, Elson, and Webb; this technique has been used 
extensively to determine size, kinetics, binding properties, concentration, or diffusion 
speed of fluorescent molecules.43 We use this technique to study the dynamics of amyloid 
β oligomer dissociation as it is non-invasive, has high resolution, and allows for low 
sample volume and short sampling time.  
The fluorescence intensity is measured by exciting the sample with an argon laser. 
The beam is focused on a high numerical objective by a dichroic mirror and the 
fluorescence emission from the sample is collected by the same objective. A high 
numerical objective is used to obtain the best collection efficiency and therefore a high 
spatial resolution. The emission is then focused on the detector by dichroic mirrors while 
stray light is blocked by a pinhole, this setup is shown in Figure 2.1. Our FCS uses two 
photomultiplier tube (PMT) detectors which requires a beamsplitter to divide the excited 
photons between the two PMTs.  The PMTs then collect the emission from the excited 
sample and can be cross-correlated to correct for detector noise. When photons strike the 
photocathode, electrons are released and accelerated in an electric field towards a series 
of dynodes. Each dynode is about 100 V more positive than the previous therefore more 
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electrons are generated at each and the signal is amplified, as shown in Figure 2.2. The 
amplified signal is then used by the computer to generate an autocorrelation curve, G(τ), 
which is used to determine sample characteristics.  
Figure 2.1: FCS Setup. Reprinted from reference: Wöll, D., Fluorescence Correlation 
Spectroscopy Studies of Polymer Systems. Springer Springer Series on Fluorescence 
(Methods and Applications), 2016; Vol. 16 
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Figure 2.2: Schematic of PMT. Reprinted from reference: Components of the confocal 
microscope. http://www.ammrf.org.au/myscope/confocal/confocal/lasers.php  
2.2.1 FCS Theory 
As mentioned above FCS measures fluorescence intensity fluctuations due to 
sample excitation. This fluorescence intensity, I (t), can be determined by measuring the 
average intensity over time, <I (t)>, and the fluctuation in intensity, δ I (t). This can be 
shown mathematically by: I (t) = <I (t)> + δ I (t). The autocorrelation function then gives 
the correlation between intensity at time, t=0 and the intensity at a later time: G (τ) =
<δ I (t)•δ I (t+ τ)>t
<𝐼 (𝑡)>2𝑡
 .  This can be used to determine the self-similarity of the fluorescence 
fluctuations at lag time, τ, by measuring the signal at different lag times. As the lag time 
increases the self-similarity decreases. We expect a good autocorrelation to have a lag 
time of τ=0.  The autocorrelation for diffusing molecules defined by a one component fit 
can be represented as:  𝐺(𝜏) =  
1
𝑁
• (1 +
𝜏
𝜏𝐷
)−1 •  (1 +  
𝜏
𝛾2𝜏𝐷
)−1/2 or 𝐺(𝜏) =  
1
𝐶𝑉
•  (1 +
𝜏
𝜏𝐷
)−1 •  (1 + 
𝜏
𝛾2𝜏𝐷
)−1/2 where N is the average number of molecules in the confocal
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volume (V), τD  (τD= w2/4D)  is the dwell time or time spent in the confocal volume and γ 
is the structure factor, or axial ratio of the confocal volume (γ=z/w, where z is the height 
of the confocal volume and w is the radius).  The confocal volume, or volume of solution 
in focus, can also be determined if the radius (w) and height (z) of confocal volume are 
known using, V= π3/2w2z. For our measurements rhodamine 110 was used as a calibration 
standard; with known diffusion coefficient of 440 μm2/s.44   The diffusion coefficient, D, 
is then determined using: D= w2/ ατD, where α= 4 for one photon excitation and 8 for two 
photon excitation.  
However the autocorrelation function changes when there is more than one 
diffusing species therefore for two-component fit the equation is: 𝐺(𝜏) =  
1
𝑁
•  ( 𝑝1  •
 (1 +
𝜏
𝜏𝐷1
)−1 • (1 +  
𝜏
𝛾2𝜏𝐷1
)−
1
2) + ( 𝑝2  •  (1 +
𝜏
𝜏𝐷2
)−1 •  (1 +  
𝜏
𝛾2𝜏𝐷2
)−
1
2))  where pi is the
fractions of particles of species, i. This two-component fit is accurate for species that 
have at least a 5-fold difference in size.35  
The diffusion coefficient is one of the more important measurements obtained by 
FCS as it is used to determine size of the molecules diffusing through the confocal 
volume using the Stokes- Einstein equation: 𝐷 =
𝑘𝐵𝑇
6𝜋𝜂𝑅ℎ
  where kB is Boltzmann’s
constant, T is the temperature, η is the viscosity, and Rh is the hydrodynamic radius. It is 
important to understand that as the diffusion coefficient increases as the size of the 
fluorescent particle decreases (smaller molecules move faster). 43, 45-46  
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2.2.2 FCS Triplet State 
Single molecule detection requires high emission of excited fluorophores. This 
leads to the probability of photons moving from the excited singlet to the triplet state 
before relaxing back down to the ground state, Figure 2.3 B. The intersystem crossing of 
singlet to triplet is nonradiative and slower (μs-ms) than the singlet to singlet (ns) 
therefore there is a delay in fluorescence.47 This delay is due to the dye being between a 
light emitting state (S1) and a dark state (T1). This leads to photo-blinking and the emitted 
fluorescence and applied excitation to no longer be proportional.48 The triplet state 
therefore causes a distortion of the autocorrelation curve, seen as an upswing, shown in 
Figure 2.3A. Since the autocorrelation function changes in amplitude and shape due to 
the triplet state the calculated N and τD would become inaccurate.49 Therefore, the 
autocorrelation function must change in order to account for the triplet state  effect and 
the equation becomes:  G triplet (τ) = ((1 – pt +(pt • exp (-τ/τt)))/ (1-pt)) • (
1
𝑁
) •  ((1 +
𝜏
𝜏𝐷
)−1 •  (1 + 
𝜏
𝛾𝜏𝐷
)−
1
2)) where pt is the fraction of particles that are in the triplet state, t,
and is proportional to the amount of photoblinking. 45, 48, 50 
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Figure 2.3: A. Shows FCS curve with triplet state. B. Shows Jablonski diagram of 
intersystem crossing from excited singlet to excited triplet state. 
2.3 Materials and Methods 
2.3.1 Materials  
The following were purchased from Sigma-Aldrich (St. Louis, MO); Amicon 
ultra-15 centrifugal filter (50K cutoff), small molecules from APEX Screen 5040 
compound library, 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP), trifluoroacetic acid (TFA), 
Tween 20, dimethyl sulfoxide (DMSO), polyethylene glycol bisphenol A epichlorohydrin 
copolymer (PEG 15-20kDa), rhodamine 110 (R110) (Abs/Em maxima = 496/ 520 nm), 
Alexa 488 (Abs/Em=495/519nm), Atto 488 (Abs/Em= 504/521nm), bovine serum 
albumin (BSA), urea, and guanidine hydrochloride (GdnHCl). Polyethylene glycol 8 
kDa, Eppendorf tubes, and Phosphate buffered saline (PBS) 10X were purchased from 
Fisher Scientific (Waltham, MA). N-α-biotinyl-Aβ (1-42), fluorescein-Aβ(1-42) 
(Abs/Em=494/521nm), Hilyte Fluor 488-Aβ(1-42) (Abs/Em = 503/528nm, fluorescein 
(Abs/Em= 490/514nm), and Hilyte Fluor 488 (Abs/Em= 502/527 nm) were purchased 
24 
from Anaspec (Fremont, CA). WT-Aβ (1-42) was purchased from rPeptide 
(Watkinsville, GA). Poly-L-Lysine-graft-polyethyleneglycol) (PLL-g-PEG) was 
purchased from SuSoS AG (Switzerland).  
2.3.2. Sample Preparation for FCS studies  
2.3.2.1 Preparation of 30nM fluorescein labeled Aβ (1-42) oligomers for FCS 
First 9.1 μl of 0.2mg/ml of fluorescein labeled Aβ1-42 monomer was mixed with 
5.1 μl of 1mg/ml wild type Aβ1-42 peptide in a 0.5 ml Eppendorf tube, which was 
determined to bind minimal Aβ (Fisher 02681248), containing 25 μl HFIP. The use of 
HFIP helps to break up aggregates so that the final sample is only monomer as HFIP 
dissociated insoluble β sheet fibrils converting it into monomer. 51The mixture was then 
dried to a thin film under filtered air to remove HFIP and 500 μl DMSO was added to 
dissolve the dried film this solution was stored at room temperature in the dark and was 
vortexed every 5 minutes. After 15 minutes the DMSO-solubilized fluorescein labeled 
Aβ1-42 was diluted 100-fold into 50 ml of 50mM NaPi-150mM NaCl, pH 7.5 (an acidic 
pH would lead to fibrils) (OFB) in a polypropylene tube and mixed rapidly and stored at 
room temperature in the dark. After 30 minutes the assembly reaction was stopped by 
adding 500 μl of 10 mg/ml polyethyleneglycol bisphenol A epichlorohydrin (PEG 15-20 
kDa) copolymer that had been filtered through a 0.22 μm pore-size filter. The solution 
was then concentrated by centrifugal filtration through a 50 kDa cutoff membrane at 
3900 rpm at 8 °C in a swinging bucket rotor. After concentration, residual monomer was 
washed through the membrane with 10 ml of OFB containing 100 μl PEG 15-20 kDa, 
which helped to block the membrane from adsorbing the oligomers, and this wash step 
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was repeated 1-5 times to reach the desired concentration. Oligomers were then stored in 
50 μl aliquots at -80 °C.  
Figure 2.4: Preparation of 1:4 FAM: WT Aβ (1-42) oligomers for FCS 
2.3.2.2 Preparation of Amyloid beta monomer for FCS 
5 μl of 0.2 mg/ml FAM-Aβ 1-42 in HFIP was mixed with 50μl HFIP in a 0.5 ml 
colored Eppendorf tube. This was then dried to a thin film under air and an equivalent 
volume of trifluoroacetic acid (TFA) was added and the mixture was incubated at room 
temperature for 10 minutes in the hood to disaggregate seeds. The sample was then dried 
to a thin film under air and the same volume of HFIP was added and mixed then dried 
under air. Then film was then dissolved in 50μl of DMSO and used for FCS 
measurements immediately (if frozen the sample would form oligomers).  
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2.3.3 Instrumental setup 
All FCS studies were performed on an ISS Alba FCS system coupled with a 1.2 
numerical aperture (NA), 60X Nikon Ti-U microscope. The fluorescently labeled Aβ (1-
42) was excited with a 488nm continuous wave laser diode and emitted radiation was
filtered by a 530 nm long-pass filter. This emission signal was detected by two separate 
photomultiplier tubes (PMTs) and the measured autocorrelation functions were cross-
correlated and analyzed with Vista Vision 4.0 software (VWR, Radnor, PA). Three 
different concentrations, 2.5 nM, 5 nM or 10 nM, of free rhodamine 110 (D= 440 μm2s-1) 
were used to calibrate the confocal volume axial and radial dimensions (w and z) with a 
60 second sample time for each measurement. A sampling frequency of 200,000 Hz with 
a laser intensity of 130-180 μW was used for all measurements.  
2.3.4 Time course of FAM-Aβ (1-42) oligomer dissociation by FCS 
Prior to measurement by FCS Aβ (1-42) oligomer mixture was diluted 30-fold 
from the 30nM stock solution with 1X PBS and loaded into a NUNC LabTek 8-well 
microscopy chamber (Nalge Nuc, Penfield, NY), for a final volume of 300 μl. A series of 
compounds from the APEX Screen 5040 compound library, which were previously 
determined to be Aβ oligomer dissociators by LeVine37, 41-42, were dissolved in either DI 
water or DMSO to make 1mM stock solution. For compounds dissolved in DMSO, Aβ in 
pure DMSO at the same concentration used to dissolve the compounds (0.1 % v/v) was 
measured for comparison. The stock was added in the appropriate amounts to the diluted 
Aβ to give a final concentration of either 1μM, 3μM, 6μM or 10μM, each chamber was 
then measured at room temperature over time. The effect of protein denaturants, urea, and 
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Gdn HCl on Aβ oligomers was also studied. Each experiment was done in triplicate and 
standard deviation was calculated for error bars.  
2.3.5 Coating NUNC chambers before measurements by FCS 
We also studied the effect of using different coatings on the NUNC chamber to 
limit adsorption of the oligomers to the surface. Prior to measurements 300μl of 1mg/ml 
Tween 20, PEG 8K, PLL-g-PEG, or PEG 15-20K was added to the chamber and allowed 
to incubate overnight before being washed several times with 1X PBS. The diluted 30-
fold Aβ oligomer sample was then loaded into the blocked chambers and measured by 
FCS over time. The effect of adding 66nM, 200nM, 250nM or 500nM WT-Aβ monomer 
to 1nM FAM-Aβ monomer was also studied.33 
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Chapter 3: FCS Results and Discussion 
3.1 Proof of two-component FCS fitting  
The accuracy of our FCS to perform a two-component fit was tested using Alexa 
488, which has a similar diffusion coefficient as fluorescein. First, 10 nM free Alexa 488 
was measured to determine the confocal volume parameters by fixing the diffusion 
coefficient to 415 μm2/s (Rh=0.5 nm) which the known literature value for Alexa 488 
standard dye.44 The calculated confocal volume radius (w) and  height (z) obtained were 
then used in subsequent measurements. Next, Alexa 488 labeled BSA was measured by 
FCS  and gave a diffusion coefficient of 67 μm2/s; which was in agreement with 
previously reported diffusion coefficients and corresponds to hydrodynamic radius (Rh) 
of 3.4 nm.52 Then three samples were prepared to test the two-component fitting accuracy 
of the FCS containing three different ratios (1:1, 1:3, 3:1) of Alexa 488 free dye and BSA 
bound Alexa 488. The samples were measured for 60 s at ~170 μW laser power and the 
diffusion coefficients for Alexa 488 and BSA were fixed to the experimentally 
determined values for each independently. Two component fits with only one free fitting 
parameter, 𝑝1, the fraction of component one, was used to experimentally determine the
ratio of free dye to labeled protein. The ratios obtained were then compared to the 
theoretical ratios based on the sample preparation using statistical significance analysis, 
which gave a p-value of 0.98. Since this is much greater than 0.05; we can say that there 
is not a significant difference between the observed and theoretical fractions. However, 
the theoretical data still does not perfectly match the experimental. This is explained by 
the fact that our BSA is not 1:1 Alexa: BSA and contains 40% free Alexa 488 (Sigma 
Aldrich). Therefore, we must multiply the observed ratios by the correction factor of 0.4. 
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Since the ratios now match, we can conclude that the two-component fitting method is 
accurate enough to distinguish between two particles with significantly different diffusion 
coefficients.  
Figure 3.1: Proving the two-component fitting method of FCS with Alexa and Alexa 
tagged BSA. Blue represents Alexa 488 and grey represents BSA tagged with Alexa. The 
fractions obtained by FCS are consistent with the mixture preparation once a correction 
factor was determined for free dye.  
3.2 FCS Determination of diffusion coefficient for monomer vs oligomer 
Before we can determine the effects of small molecule modulation on Aβ 
oligomer dissociation we must first determine the size differences between free 
fluorescein, monomer, and oligomer which is shown in Figure 3.2 A. Using one- 
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component fitting for free dye and monomer and two component fitting for oligomer we 
determined the diffusion coefficients to be 425 μm2/s, 188 μm2/s, and 10 μm2/s 
respectively. We then used the Stokes-Einstein equation to calculate the hydrodynamic 
radius to be 0.5 nm for free dye, 1.2 nm for Aβ (1-42) monomer, and 25 nm for Aβ (1-42) 
oligomers, which all agree with recent literature values.16, 44  
We were able to prove the need for a TFA treatment during monomer preparation, 
as mentioned in chapter 2.3.2.2, to obtain a sample of pure monomer as TFA breaks up 
multimeric complexes. When TFA was not used, a two-component fit was found to be 
necessary to describe the autocorrelation curves; where D2 fixed was to 10 μm2/s and the 
sample was found to 20 % oligomer. After TFA treatment, shown in Figure 3.2 B, a one-
component fit gave a diffusion coefficient of 188 μm2/s which corresponds to a Rh of 1.2 
nm, which is in reasonable agreement with previously published Rh values of 0.9-1.4 nm 
for monomers of Aβ.16 We were also able to confirm that the oligomer sample, prepared 
as outlined in chapter 2.3.2.1, does in fact contain monomer and oligomer as the sample 
cannot be fit by a one component fit, Figure 3.2 C. The experimentally determined values 
for D for both monomer and oligomer were then used to fix the diffusion coefficients 
during dissociation studies. Later I will discuss how in some samples this approach failed 
and best fits were made by fixing D monomer and allowing D oligomer to vary; 
suggesting that oligomers are shrinking in size over time. Lastly, unlike monomer or 
oligomer, fluorescein is best fit with a one-component fit with a triplet state, Figure 3.2 
D, likely due to self-quenching of the dye, which also explains why fluorescent counts 
are observed to increase as oligomer dissociates.  
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Figure 3.2: A) FCS showing free dye, Aβ (1-42) oligomers and Aβ (1-42) have different 
diffusion rates. B. FCS one-component fit of Aβ monomer, Rh= 1.23 nm. C. FCS two 
component fit of Aβ (1-42) oligomers, Rh=25.8 nm. Red line shows a one component fit 
of oligomer and monomer mixture does not work.  D) FCS curve of fluorescein, Rh= 0.5 
nm, fit with a one-component fit with a triplet state.   
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3.3 Importance of using PEG during oligomer concentration 
As mentioned previously in section 2.3.2, a PEG (polyethylene glycol) polymer was 
required to keep Aβ oligomers from binding to the filter during concentration. The PEG 
used was 15-20kDa and synthesized with a bis-phenol A core, as depicted in Figure 3.3. 
In fact, an FCS signal is not detected in the concentration flow-through; proving 
oligomers do not leak through the filter membrane during the concentration step. 
Previous FCS dissociation studies were performed on oligomers prepared without the 
extra wash step discussed in chapter 2.3.2.1. This preparation resulted in mixtures of 
approximately 50% oligomer and 50% monomer being formed (Figure 3.5 A). Our more 
recent preparation, using the extra OFB with PEG washes, allows us to concentrate the 
sample to approximately 80% oligomer (Figure 3.8). While there is concern that the 
presence of PEG may modify the oligomer size or influence the reaction mechanism, it is 
found to be necessary to prepare high fractions of Aβ oligomers for use in our 
dissociation studies.  
Figure 3.3: Structure of PEG synthesized with a bis-phenol A core. 
3.4 Oligomer dissociation in DMSO using FCS 
Aβ dissociation was first studied in dimethyl sulfoxide (DMSO) as DMSO is used for 
dissolving the monomer film during the oligomer preparation as mentioned previously in 
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section 2.3. Therefore, it is important to determine if DMSO not only inhibits oligomer 
assembly but if it also leads to dissociation as well.  Our results, as seen in Figure 3.4, 
suggest that oligomer dissociation is dependent on DMSO concentration, as expected. 
While 0.1% v/v is equal to the intrinsic dissociation rate, of 10% in 6 hours; when higher 
concentrations such as 1% v/v or 3% v/v DMSO is used, dissociation is increased to 25-
30 % over 6 hours. While our results and previous work done by the DeRouchey lab 
show that DMSO is a useful solvent for dissolving the monomer film during oligomer 
preparation, it is important to use the lowest concentration possible as to not interfere 
with oligomer formation. Furthermore, as 1% and 3% appear to dissociate at the same 
rate, concentrations between 0.1% and 1 % should be tested to determine the best 
concentration to use to preserve the oligomer stability.    
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Figure 3.4. DMSO induced Aβ dissociation is DMSO concentration dependent. Aβ 
dissociated 25-28% when 1% v/v DMSO or 3% v/v DMSO was present but showed 
almost no dissociation in 0.1% v/v DMSO.  
Furthermore, we also wanted to determine if 3% v/v DMSO dissociates Aβ oligomers 
immediately, therefore we compared the fraction of oligomers present in the sample 
before adding DMSO and after adding DMSO. As shown in Figure 3.5 B we observed an 
8-10 % decrease in the oligomer fraction when DMSO is added, t1. Furthermore, Figure
3.5 B suggests that only the oligomer fraction is decreasing in 3% v/v DMSO.; as the data 
is well described by a two-component fit where the monomer and oligomer size are kept 
constant and only the fraction of oligomer is changing with time. This suggests a 
dissociation mechanism where oligomers cooperatively dissociate leading to the near 
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instantaneous formation of monomers as intermediate sized oligomers are not observed 
by FCS.  
Figure 3.5: A) Oligomer FCS fit before DMSO was added B) Dissociation of Aβ in 
3% v/v DMSO after 6 hours, black= 0h, red=6hr, where size says constant at Rh= 30 
nm and % oligomer decreases 28% in 6 hours.  
3.5 Oligomer dissociation in 2,5 DHBA and oligomer stabilization by 3,4,5 THBA 
Previously, our collaborator Dr. LeVine studied a Apex Screen 5040 compound 
library using ELISA methods and identified potential dissociators.41-42 The most potent 
dissociator in that study was found to be 10 μM 2,5 dihydroxybenzoic acid (2,5 DHBA), 
Figure 3.6 A, therefore this was chosen as a starting point.41 The prepared  1nM 1:4 Fl-
Aβ:WT-Aβ was incubated with 10μM 2,5 DHBA and oligomer fraction was determined 
with FCS two-component fits every hour for 6 hours. As shown in Figure 3.7 below 2,5 
DHBA binds to Aβ oligomers and reacts with the peptide in a way that increases its 
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dissociation around 20 %. Similar to DMSO, as shown in Figure 3.8, the size of 
oligomers does not change when incubated with 2,5 DHBA only the fraction of 
oligomers decreases. This data is consistent with cooperative dissociation where smaller 
intermediates are not formed, and LeVine’s hypothesis, which stated that oligomers 
decrease in number but not size in the presence of 2,5 DHBA.41  
Next, we studied the effects of gallic acid (3,4,5 trihydroxybenzoic acid (THBA)) 
on oligomer dissociation. Despite gallic acid belonging to the same class as DHBAs, the 
only difference being the extra hydroxy group (Figure 3.6 B), surprisingly the LeVine 
study observed that gallic acid stabilized Aβ oligomers.41 As seen in Figure 3.7, we also 
observe the stabilizing effects of gallic acid on Aβ by FCS. When the 1:4 Fl-Aβ/WT-Aβ 
was incubated with 10μM gallic acid we observed that the dissociation after 6 hours was 
equal to the intrinsic dissociation of Aβ. After a 24-hour incubation in gallic acid 
interestingly, the fraction of dissociated oligomers was decreased only 43% compared to 
the 90% dissociation observed in intrinsic Aβ oligomers.  
Next, we investigated if this stabilization occurred in the presence of 10 μM 2,5 
DHBA. FCS revealed that the Aβ dissociation with 10 μM 2,5 DHBA and 10μM gallic 
acid was equal to the intrinsic dissociation of Aβ oligomer after a 6 hour incubation, 
which was consistent with LeVine’s study.41 We therefore hypothesize that gallic acid 
may be competing with 2,5 DHBA for the same binding sites on Aβ thus blocking 2,5 
DHBA attachment and preventing dissociation.41  More experiments with time points 
after 6 hours are needed to validate this hypothesis.   
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Figure 3.6: Chemical structures for A. 2,5 DHBA and B. Gallic acid. 
Figure 3.7: Percent of original oligomers left in solution after 0h, 3h, 6h and 24h 
incubation in 10 μM 2,5 DHBA and gallic acid. 
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Figure 3.8: FCS curve of 1nM Aβ (1-42) oligomers incubated in 2,5 DHBA for 6h (red). 
Oligomer fraction decreases 30% in 6 hours while the size of oligomers, Rh, stays 
constant, consistent with a cooperative dissociation model.  
3.6 Oligomer dissociation by protein denaturants 
Next, we used FCS to monitor Aβ oligomer dissociation in the presence of 
common protein denaturants, urea and guanidine hydrochloride (Gdn HCl), Figure 3.9. 
These denaturants are known to cause protein unfolding by binding to the peptide bonds 
in order to destabilize the peptide.53 Surprisingly, we see by FCS that these denaturants 
dissociate Aβ oligomers differently than DMSO or 2,5 DHBA. As seen in Figure 3.10 A 
the autocorrelation functions of the Aβ oligomers incubated in 8M urea are not well 
described with two-component fits where both the monomer and oligomer diffusion 
coefficients are fixed. Instead, the data is well-described by a model that suggests that 
while the monomer fraction is increasing, the size of the oligomers is decreasing.  
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As shown in Figure 3.10 B, oligomer size rapidly decreases 23 nm in six hours. In 
fact, the size of oligomers decreases almost immediately when incubated in 8M urea; 
decreasing from 31 nm to 16.6 nm, in the time between when urea was added and the 
first measurement. After 6 hours, Rh decreases further to 7.9 nm. Interestingly, 8M urea 
does not significantly change the total oligomer fraction from that of Aβ native 
dissociation.  Aβ oligomers were observed to intrinsically dissociate 10% in 6h while 8M 
urea only increased the rate 10% as 20% dissociation was observed in the same amount 
of time. Therefore, we hypothesize that urea is a partial linear dissociator, however more 
studies are needed to prove this hypothesis.  
Figure 3.9: Chemical structures of A. urea and B. Gdn HCl. 
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Figure 3.10: A shows FCS result suggesting urea is a linear dissociator, as when D of 
oligomer is fixed, blue, the fit does not describe the data well, so D oligomer must be left 
free, red.  B shows the summary of the change in Rh in 8 M urea over the 6-hour 
incubation.  
Next, Gdn HCl was tested to see if it is a strong linear dissociator or a partial 
linear dissociator like urea. Aβ was first incubated with 1 M Gdn HCl, as shown in 
Figure 3.11 A. However, these results do not necessarily prove Gdn HCl is a linear 
dissociator; as when D oligomer was left free the best fit was essentially the same as the 
fixed value. Therefore, the concentration was increased to 4M, Figure 3.11 B, and now it 
is clear that Gdn HCl is a linear dissociator like urea, as fixing D oligomer to the standard 
value for Aβ red curve does not work.  
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Figure 3.11: A. FCS curve for Aβ linear dissociation induced by 1M Gdn HCl, blue, 
however fitting for coperative dissociation also works, red. B. FCS curve for Aβ linear 
dissociation induced by 4M Gdn HCl, proving this compound is in fact a linear fit.  
As seen in Figure 3.11 and 3.12 while 1M Gdn HCl cannot be accurately 
determined to be a linear dissociator, it still led to a significant 63% decrease in the 
oligomer fraction as well as an 11 nm decrease in oligomer size. Furthermore, as seen in 
Figure 3.12, 4M Gdn HCl decreased size of oligomers by 16nm and oligomer fraction by 
54% in 6 hours. These results suggest a linear concentration dependent dissociation of Aβ 
in Gdn HCl.  
However, the next question was to determine if gallic acid influenced linear 
dissociators or only cooperative dissociation by 2,5 DHBA. Therefore, 1nM 1:4 Fl-
Aβ/WT-Aβ was incubated with 10 μM gallic acid and 1M Gdn HCl, as shown in Figure 
3.12. While gallic acid prevented the decrease in oligomer fraction our results show 
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oligomers still shrink by 8-9 nm.  Therefore, more experiments are needed to verify if 
gallic acid stabilizes Gdn HCl induced Aβ oligomer linear dissociation.  
Figure 3.12: A shows dissociation rate for Aβ oligomers in various concentrations of 
Gdn HCl. B shows the decrease in Rh.  
The last experiment with Gdn HCl was to increase the concentration to 8 M, when 
incubated in 8M Gdn HCl oligomer Rh rapidly decreased from 26 nm to 2-3 nm, Figure 
3.12. Furthermore, as shown in Figure 3.13 the FCS curve is best fit with a one 
component fit, black curve, Figure 3.13 B. This proves large oligomers were no longer 
present after 8M Gdn HCl treatment. Rather it appears that the large oligomers 
completely dissociate into small oligomers of dimers or trimers. However, as mentioned 
in Ch. 2.2 for a two-component fit to be accurate the molecules must have a 5-fold 
difference in their size.35 Therefore monomer (Rh=1.2 nm) is still present and would still 
be the predominate species but the size is not significantly different enough for the two-
component fit to work and the presence of a few dimers/trimers biases the result. 
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However, the formation of these dimers and trimers in 8 M Gdn HCl proves Gdn HCl is a 
complete linear dissociator while urea is a partial linear dissociator.  
Figure 3.13: A. FCS curve for Aβ oligomer linear dissociation to 2-3 nm small oligomer 
intermediates in 8M Gdn HCl. B. FCS curve showing a one-component fit had to be 
used, black. Red fit is two-component fit for monomer and large oligomers.  
3.7 Oligomer dissociation by other ApexScreen 5040 compounds 
As mentioned previously our collaborator Dr. LeVine previously identified 
several potential Aβ dissociators by ELISA.41-42, 54 Since we saw similar results to Dr. 
LeVine when comparing our FCS study of 2,5 DHBA induced dissociation of Aβ 
oligomers, we selected three more compound classes from the Apex Screen 5040 library: 
rhodamines, quinolines, and benzimidazoles. Previous studies have shown these 
compound classes are useful probes of AD pathology as they have high affinity for 
binding tau and a lower affinity for Aβ fibrils, however their effect on oligomers is not 
well understood.55 Since DMSO was used to solubilize the compounds it served as a 
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control for these studies. The first compound monitored by FCS for Aβ dissociation was 
a benzimidazole derivative, Figure 3.14 A, labeled as 2C9 (number refers to location in 
library). As shown in Figure 3.14 B, 2C9 was found to be a very potent dissociator using 
FCS. As shown in Figure 3.14 B, incubation of Aβ oligomers in 10μM 2C9 resulted in a 
20% decrease in oligomer fraction upon addition. After the 6-hour incubation 56% of the 
oligomer fraction was observed to dissociate. Since the oligomer fraction decreased 
rapidly in 10μM 2C9 we decided to do a dose response curve to better understand the 
dissociation rate. As shown in Figure 3.15, the dissociation of oligomer is dependent on 
2C9 concentration, as the fraction of oligomers decreases with increasing concentration 
of 2C9 at each time point. Interestingly, the oligomers were not observed to dissociate 
further between when 2C9 was first added, 0.5h, and the last time point at 5h, which was 
not observed in the first experiment, Figure 3.14 B. The faster dissociation rate could be 
attributed to the fact fresh 2C9 was prepared on the same day of the experiment. 
Furthermore, the data was fit by fixing the D of both monomer and oligomer, consistent 
with the corporative dissociation.  
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Figure 3.14: A. General base structure of benzimidazole derivatives. B. Shows decrease 
in oligomer fraction in 10μM 2C9 over 6 hours.  
Figure 3.15:  Dissociation time course of 1nM Aβ (1-42) oligomers in 2C9. 
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Next, we used FCS to monitor Aβ dissociation in the presence of a rhodanine 
derivative, Figure 3.16 A, 22D6.  While rhodanines are known to be tau aggregation 
inhibitors little is known about their interaction with Aβ oligomers.56 Surprisingly, our 
FCS results show that dissociation did not occur; as DMSO and 22D6 had the same 
dissociation rate, Figure 3.16 B. These results are explained by the fact that the ester form 
(inactive) was used rather than the acid form (active) and therefore giving us a 
comparison for the other ApexScreen 5040 compounds.  
Figure 3.16: A. General base structure of rhodanine derivatives. B. Shows 0.1% v/v 
DMSO and 10μM 22D6 have the same dissociation rate. 
Previously, Dr. LeVine and collaborators used ELISA studies to show that 
hydroxyquinolines inhibit Aβ oligomer formation but do not dissociate Aβ oligomers 
once formed.42 Typically, these compounds would react with Aβ by chelation however 
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his results proved that this was not necessarily the only means of inhibition.42  Therefore, 
we decided to use FCS to investigate if quinoline derivatives, Figure 3.17 A, 39H8 and 
39A8 would dissociate oligomers. FCS revealed that both quinoline derivatives 
cooperatively dissociate Aβ as oligomer size remained constant while oligomer fraction 
decreased, Figure 3.17 B. Furthermore, incubation of Aβ oligomers in 10 μM 39A8 or 
39A8 result in a 45-53% decrease of the oligomer fraction upon addition. After a 6-hour 
incubation 65-71 % of the oligomer fraction was observed to dissociate. We also studied 
dose response with these quinoline derivatives, Figure 3.18. Similar to 2C9, dissociation 
with 39H8 is concentration dependent as the dissociation was increased at each time 
point with increasing concentration. Interestingly, for 39A8 6 μM was more potent than 
10 μM, therefore more studies need to be done to confirm the concentration dependence. 
Figure 3.17: A. General base structure for quinoline derivatives. B. Shows dissociation 
rate for Aβ oligomer incubation with 10 μM 39H8 and 10μM 39A8. 
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Figure 3.18: A. Dissociation time course of 1nM Aβ (1-42) oligomers in 39A8. B. 
Dissociation time course of 1nM Aβ (1-42) oligomers in 39H8.  
3.8 Coating NUNC Chamber 
Due to a series of unexpected results and a sudden decrease in fluorescent 
intensity with time, Figure 3.19 A, we assumed our sample was photobleaching.39 
Normally we see fluorescence increase as oligomers dissociate due to increased free dye 
in solution. As this change occurred after a laser realignment, our first thought was that 
this decrease in fluorescence was caused by having the laser power set too high.39 To test 
for the appropriate power level, we measured Aβ oligomers at various laser powers, 8- 
156μW, Figure 3.19 B. However, we still see the fluorescence decrease occurring at the 
about same rate, 60-80%, for each laser power tested, even at a very low laser power of 8 
μW.  
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Figure 3.19: 1nM Aβ oligomer fluorescent counts decrease 80% with time, at ~170 μW. 
B. Testing photobleaching at various laser powers.
Next, to try to verify that the dye was photobleaching we measured a series of free 
dyes at 156 μW, Figure 3.20. We compared the free fluorescein (FAM) to R110, Alexa 
488 and Atto 488 to find a dye less susceptible to photobleaching, each dye was 
measured at 10nM concentration. However, we found free fluorescein was not 
photobleaching and in fact the fluorescence increased with repeated FCS measurements.  
Next, we decided to further test if the dye was photobleaching by measuring free FAM as 
well as free Hilyte 488 at various laser powers, as Hilyte 488 labeled Aβ can also be 
purchased from Anaspec and Hilyte 488 is known to be less susceptible to 
photobleaching than FAM. However as seen in Figure 3.21 FAM is just as stable as 
Hilyte 488 at laser powers below 200 μW.  
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Figure 3.20: A. Comparison of the change in fluorescent counts with repeated 
measurements of various free dyes at 156 μW.  
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Figure 3.21: A. Comparison of free FAM at various laser powers at t=0min and after 6 
consecutive measurements (t=30min). B.   Comparison of free Hilyte 488 at various laser 
powers at t=0min and after 6 consecutive measurements (t=30min). 
Therefore, we concluded that the fluorescence decrease was not due to 
photobleaching and could be due to a failed Aβ oligomer preparation as the oligomers 
tested were from a new batch. To verify this, we prepared and measured an Aβ monomer 
sample, Figure 3.22. We again saw an 80% decrease in fluorescent counts within 5 
minutes. Since we still saw a fluorescent count decrease in our monomer sample the 
decrease in fluorescence is not likely due to a failed oligomer preparation. 
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Figure 3.22: 1 nM Aβ (1-42) monomer decreases in fluorescence with repeated 
measurements at 156 μW laser power.  
A recent study by Wennmalm, et.al., found that Aβ decreases in fluorescence over 
time during FCS, due to Aβ adsorbing to the sample holder.33 They proved this 
hypothesis by observing that diffusion increases over time as large particles adsorb to the 
glass and smaller particles stay in solution, Figure A1. As seen in Figure 3.23 A we 
observed the same effect for the oligomer at various laser powers study, except for 
sample at 12 μW. Additionally, we see that concentration of oligomers decreases rapidly 
at each laser power further confirming that the oligomers could be adsorbing to the 
sample holder, Figure 3.23 B. Interestingly, the concentration for the sample at 22 μW 
decreased the most, ~70%; due to this large discrepancy, this measurement is likely 
inaccurate and should be repeated.  
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Figure 3.23. Diffusion speed increases (A) and concentration decreases (B) with time for 
oligomer.   
Since Wennmalm, et.al., was able to eliminate this issue by precoating the sample 
holder with  poly-l-lysine PEG, Figure A1, our next series of tests were to see if we could 
find an effective coating to limit Aβ oligomer from adsorbing to the sample holder during 
our dissociation studies, Figure 3.24.33  However, our results showed that none of the 
coatings tested improved the decrease fluorescence.  
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Figure 3.24. Coating sample chamber with different polymers (1 mg/ml) to limit 
adsorption of Aβ to the sample holder was unsuccessful, as fluorescence still decreases 
(A) and the diffusion coefficient increases (B).
We also tested PLL-PEG on the minute time scale as Wennmalm, shows Aβ will 
bind to the untreated chamber within seconds, Figure A1. Unlike this study our results 
show PLL-PEG did not improve the decrease in fluorescence or increase in diffusion 
coefficient, Figure 3.25. Therefore, it can be concluded that the PLL-PEG might be 
improving the amount of Aβ binding but does not completely block the oligomers from 
binding to the NUNC chamber.  
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Figure 3.25.  1mg/ml PLL-PEG coating does not appear to stop oligomers from binding 
the sample holder as the decrease in fluorescence (A) and increase in D (B) still occurs.  
Wennmalm, et.al., also stated that if a higher concentration than 200nM Aβ was 
used then the sample would not adsorb to the sample chamber as the excess Aβ blocked 
further binding. As seen in Figure 3.26, when we tested various concentrations of WT Aβ 
monomer added to 1nM FAM-Aβ monomer sample, the drop in fluorescent counts still 
occurs. Additionally, the concentration increases as the amount of WT-monomer present 
increases. This could be due to excess WT-monomer interacting with the FAM-monomer 
instead of the sample holder which would also explain the decrease in fluorescence. This 
experiment was not repeated in an oligomer sample as it was unsuccessful.  
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Figure 3.26: Coating sample chamber with excess WT-monomer. A shows fluorescence 
still decreases and B shows decrease in concentration.  
While our results did not match up to the Wennmalm study, our data still points to 
oligomers binding to the sample holder. Since their study showed PLL-PEG blocking Aβ 
binding we decided to use a glass slide to replicate their study and prove that the extra 
surface area of the NUNC chamber is why oligomers still bind, even with PLL-PEG 
coating. However, as shown in Figure 3.27, 1nM Aβ did not bind to the untreated glass 
slide as expected, as fluorescence and concentration increased in the sample on glass and 
decreased in the sample in the NUNC. As Wennmalm showed the oligomers binding to a 
glass cover slip within 5 minutes we next repeated our measurements using this faster 
time scale to see if our time scale was not quick enough to observe the oligomer binding. 
Furthermore, we wanted to compare the concentration used by Wennmalm, 30nM, to the 
one we use, 1nM, as increased concentration could explain an increased rate of 
absorption.  As shown in Figure 3.28, Aβ oligomers do not appear to bind to the glass 
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slide at either concentration as counts and concentration are increasing, while the 
diffusion coefficient stays relatively constant. Interestingly our results from FCS do not 
match the expected concentration, even at time zero. As mentioned earlier Wennmalm, 
et.al., observed that at 200nM Aβ the oligomers coat the glass and the PLL-PEG coating 
was not needed, which could explain why the oligomers are not binding to the glass in 
our experiment. However, it is unlikely that the Aβ would bind so quickly that the 
concentration decrease cannot be observed. Since the confocal volume was calibrated 
with 10nM R110 free dye the measurement might not be accurate enough for the 30nM 
Aβ sample; resulting in a lower value for concentration. As mentioned in Ch. 2 we used 
PEG 15-20k during the concentration of oligomers however this was not used by 
Wennmalm. Therefore, the PEG coating the oligomer could explain why our oligomers 
do not bind to the glass slide. However, as oligomers do still bind to the plastic NUNC 
moving forward it would be better to only use the glass slide.  
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Figure 3.27: A. Fluorescence counts increase for 1nM Aβ oligomer on glass slide and 
decrease for 1nM Aβ oligomer in NUNC chambers. B. Concentration is stable for 1nM 
Aβ oligomer on glass slide but decreases for 1nM Aβ oligomer in the NUNC chamber.  
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Figure 3.28: A. Fluorescence is stable for Aβ oligomer on glass slide at both 1nM and 
30nM concentration. B. Unnormalized fluorescent intensity for 1nM and 30nM Aβ on a 
glass slide. C. Diffusion of Aβ oligomers remains constant on a glass slide at both 1nM 
and 30nM concentration D. Concentration increases with repeated measurements for Aβ 
on a glass slide at 30nM and is stable for Aβ at 1nM concentration.  
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Chapter 4: Developing a TIRF imaging technique of Aβ (1-42) oligomers 
4.1 Introduction  
While FCS is useful for studying the mechanism of oligomer dissociation, 
limitations exist. The main limitation of FCS is that FCS only gives average diffusion of 
all molecules in the confocal volume. However, it is probable that all oligomers in our 
sample are not the same size. This chapter will outline the development of a TIRF 
method to measure Aβ (1-42) oligomers to overcome this limitation of FCS. By 
expanding our oligomer dissociation studies with TIRF we can analyze dissociation 
across multiple individual oligomers within the same sample. This would validate if there 
are two distinct dissociation mechanisms as observed by FCS or if there is only one 
mechanism occurring at different time scales not able to be distinguished by FCS.   
4.2. Background on TIRF 
Total internal reflection fluorescence microscopy, TIRF, is a technique used for 
the visualization of biological molecules. TIRF differs from traditional epifluorescence 
where the whole sample is excited, as the laser beam position is changed at the objective 
focal plane in TIRF to allow for less sample to be excited, Figure 4.1.  This decreases 
background fluorescence providing for out of focus fluorescence to be eliminated and 
thereby decreasing the signal to noise ratio and out of focus fluorescence.  
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Figure 4.1: Schematic showing difference between epifluorescence vs TIRF. Reprinted 
from reference: Ravier, M., et.al. Imaging a target of Ca2+ signaling: Dense core granule 
exocytosis viewed by total internal reflection fluorescence microscopy. Methods 2008, 
46:3. 233-238. 
As shown in Figure 4.2, during TIRF the laser beam is focused at the back of the 
objective focal plane and is then focused on to the glass cover slip. The laser beam then 
propagates through the transparent glass medium with a high index of refraction until it 
interacts with the sample solution which has a lower index of refraction. These refractive 
index differences between the glass and the sample therefore determine the critical angle 
of reflection, given by Snell’s law: ϴcritical = sin-1(ηg/ηs).  For the total internal reflection, 
where all light is reflected to the glass, to be achieved the incident angle must be greater 
than the critical angle. Although the light will no longer be prorogating into the sample 
the small amount of the reflected light that penetrated at the interface creates an 
evanescent wave (electromagnetic field) in the sample. This evanescent wave then 
propagates parallel to the surface in the plane of incidence and its frequency is equal to 
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the excitation frequency. However, this wave decays with increasing distance from the 
interface therefore only fluorophores within 200 nm of the coverslip are excited, given by 
E(z)= E (0) exp(-z/d), where E(z) is the energy at distance z from the interface, E (0) is 
energy at the interface, and d is the penetration depth. Also, d is dependent on the 
wavelength of incident light, the angle of incidence and the refractive indices, given by: 
d= λ
i 
/ 4π (n
g
2
sin
2 
θ - n
s
2
)
1/2. 
Then dichromic mirrors direct the emission beam to the
camera to create an image as seen in Figure 4.3. 57-58 
Figure 4.2: Schematic showing theory of total internal reflection fluorescence. Reprinted 
from reference: http://biointerfaces.mcmaster.ca/instruments/tirf/ 
The TIRF we used is equipped with a CMOS (complementary metal oxide 
semiconductor) camera mounted on the microscope controlled by Metamorph software. 
CMOS uses an array of light sensitive pixels to generate an image. CMOS is advantageous 
over other cameras as it uses less power, has a fast response time, and each pixel is 
amplified separately resulting in good sensitivity. Using this technology, we can observe 
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and measure the dissociation of each individual oligomer on the glass cover slip surface 
simultaneously, instead of the general trend of all oligomers in solution. This can help to 
validate previous findings of two distinct mechanisms of oligomer dissociation.  
Figure 4.3: Schematic of TIRF instrumental set-up.  Reprinted from reference: Lord, S. 
J.; et.al. Single-Molecule Spectroscopy and Imaging of Biomolecules in Living Cells. 
Analytical chemistry 2010, 82 (6), 2192-2203. 
4.3 Materials and Methods 
4.3.1 Materials  
The 35mm plastic Petri Dishes with glass cover slip bottoms were purchased from 
Cell E&G. The Biotin-PEG-Silane was purchased from Lysan Bio Inc. The neutravidin 
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protein was purchased from Thermofisher. The following Aβ (1-42) peptides were 
purchased from Anaspec: FAM-Labeled Aβ(1-42), WT Aβ (1-42) and Biotin-Aβ(1-42). 
4.3.2. Preparation of 1:1:4 biotin labeled: FAM labeled: unlabeled oligomers for 
TIRF analysis  
First 1.82 μl of 0.2mg/ml of biotin labeled Aβ1-42 was mixed with 1.82 μl of 0.2 
mg/ml FAM labeled Aβ and 1.02 μl of 1mg/ml wild type Aβ1-42 peptide in a 0.5 ml 
colored Eppendorf tube containing 5 μl HFIP. This was then dried to a thin film under air 
and dissolved in 5 μl TFA to disaggregate seeds and dried to a film. The film was then 
dissolved in 5 μl HFIP and dried once more to remove residual TFA. Then 100 μl DMSO 
was added to dissolve the dried film and the solution was stored at room temperature in 
the dark and was vortexed every 5 minutes. After 15 minutes the DMSO solubilized Aβ1-
42 was diluted 100-fold into 10 ml of 50mM NaPi-150mM NaCl, ph7.5 (OFB) in a 
polypropylene tube and mixed rapidly and stored at room temperature in the dark for 30 
minutes and 100 μl PEG 15-20k was added to stop the reaction. Oligomers were then 
stored in 1 ml aliquots at -80 °C and were mixed in a 2:1 ratio with 2mg/ml biotin-PEG-
silane for TIRF. 
4.3.3 Glass Modification procedure for protein immobilization 
To eliminate background fluorescence and to enable biotin-PEG-silane binding to 
the glass, the 35mm Petri dishes that were used for TIRF measurements were modified 
with base and acid, Figure 4.4. First the petri dishes were sonicated for 1 hour at 45°C in 
5M NaOH to convert the silicon dioxide to siloxane. Next the dishes were rinsed in hot 
65 
water and ethanol several times before being sonicated again in 0.1 M HCl, to covert 
siloxane to silanol. Then after rinsing in hot water and ethanol again the petri dishes were 
put in a plasma cleaner for 4-5 minutes to remove residual organic contaminates. The 
dishes were then imaged using TIRF to check for background fluorescence before being 
used for experiments with Aβ.  
Figure 4.4: Glass surface modification for attachment of Bio-PEG-Silane. Reprinted 
from reference: Nicholas, M. P.; Rao, L.; Gennerich, A., Covalent immobilization of 
microtubules on glass surfaces for molecular motor force measurements and other single-
molecule assays. Methods Mol Biol 2014, 1136, 137-69. 
66 
4.3.4 Biotin-Neutravidin linker chemistry protocol 
First 300 μl of 2 mg/ml Biotin-PEG-Silane solution was added to a clean and 
modified petri dish and allowed to incubate at room temperature for 30 minutes. Then the 
petri dish was washed with ethanol several times. Then 300 μl of 0.1 mg/ml neutravidin 
in PBS buffer (pH 7) was added and allowed to incubate for 2 hours. After rinsing out the 
neutravidin several times with PBS buffer (pH 7), 300 μl of 2:1 v/v 2 mg/ml biotin-PEG-
silane: prepared 0.03μM 1:1:4 biotin-Aβ (1-42): FAM-Aβ (1-42): WT Aβ (1-42) 
oligomers were added and incubated for 30 minutes. The 2:1 ratio of biotin to labeled 
oligomers helped to eliminate non-specific binding by blocking the surface of the glass 
cover slip. Furthermore, controls were run to verify binding efficiency; the first was 
without adding the Aβ and the second was one where 1:10 Aβ: Biotin was used.  
67 
Figure 4.5: Immobilization of prepared Aβ (1-42) oligomers for TIRF. 
4.3.5 Instrumental Setup 
All images obtained using objective style total internal reflection fluorescence 
microscope equipped with an inverted microscope (Olympus ix83). Samples were excited 
with 488nm laser which was focused onto the Olympus, 1.5 NA, 60X, oil immersion 
objective. To obtain TIRF the beam was focused on the back aperture of the objective 
lens with a stepper motor. 59 The CMOS camera then detected the signal to generate an 
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image using MetaMorph software (MDS, San Jose, CA). The camera was set to a frame 
read time of 200 ms and the binning was set to 4 X 4 (250 pixels X 250 pixels). 
Autofocus was also used to eliminate drift.  
4.4 Results and Discussion 
The major difference between our FCS studies and our TIRF studies is that 
oligomers are fixed on a glass cover slip for TIRF instead of flowing free in solution.  To 
attach the oligomers to the glass we must first “clean the surface” as outlined previously 
in 4.2.3. This helps not only to remove contaminants but by using HCl and NaOH we can 
convert silicone dioxide to siloxane then to silanol, as silanol is more reactive with the 
silane.60 Without this cleaning step it would be impossible to get the Bio-PEG-Silane to 
attach to the glass and even it did we would not be able to distinguish sample from 
contaminates, Figure 4.6.  
Figure 4.6: A shows glass cover slip that had not been cleaned and B shows one that has. 
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The first experiment with Aβ and TIRF was a negative control in order to 
determine the order components should be added in order to observe the immobilized Aβ. 
At first, we used unlabeled biotin-Aβ (1-42) oligomers instead of Biotin-FAM-Aβ (1-42) 
to prove that the protein must be labeled in order to be observed by TIRF. The procedure 
in Ch. 4.3.4 was followed however, due to the fact the oligomers were not fluorescently 
labeled, we had to add 1mg/ml streptavidin 488 after allowing the oligomers to bind. This 
extra step, as seen in Figure 4.7, resulted in a high amount of background fluorescence. 
Therefore, to eliminate the extra background fluorescence, we changed the oligomer 
preparation to make 1:1:4 biotin Aβ: FAM Aβ: WT Aβ, as outlined in Ch. 4.3.2, instead 
of using 1:1 biotin Aβ: WT Aβ. 
Figure 4.7: Epifluorescence image where unlabeled biotin-Aβ (1-42) with streptavidin 
488 was attached to the glass cover slip.  
After we optimized the cleaning procedure and the oligomer preparation 
procedure we imaged a series of controls. As shown in Figure 4.6, the cleaning procedure 
was efficient, and nothing appears in the TIRF if fluorescently tagged protein is not 
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added.  As shown in Figure 4.8 B, the 1:1:4 Bio-Aβ/Fl-Aβ/WT-Aβ oligomers will attach 
to the neutravidin functionalized surface, however, the data analysis is difficult due to the 
number individual oligomers in our sample. Therefore, to limit the non-specific binding, 
we decided to dilute the Aβ before attaching it to the coverslip. We first used a 10:1 ratio 
of biotin-PEG-Silane: 30 nM 1:1:4 Bio-Aβ/Fl-Aβ/WT-Aβ, however as seen in Figure 4.8 
C this ratio was too high. Next, we decided to lower the ratio to 2:1 Biotin-PEG-Silane: 
Aβ, as seen in Figure 4.8 D, which was then used for subsequent TIRF studies. 
Figure 4.8: TIRF controls. A shows a sample where only biotin and neutravidin were 
added to the cover slip. B shows 30nM Aβ bound to the cover slip. C shows 10:1 Biotin-
PEG-silane: Aβ bound to the cover slip. D shows 2:1 biotin-PEG-silane: Aβ bound to the 
cover slip. 
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After establishing a dilution factor, the prepared 1:1:4 Bio-Aβ/Fl-Aβ/ WT-Aβ was 
incubated with 40μM 2,5 DHBA and imaged with TIRF every 30 minutes for 6 hours. 
This concentration was chosen as it was assumed that a higher concentration would be 
necessary as bound oligomers would be more difficult to dissociate then those free in 
solution. As shown in Figure 4.9, data analysis using ImageJ is challenging. Typically, 
we would select the bound oligomers in time frame 1 and the software would then 
measure all frames simultaneously. So far, we have not been able to effectively use this 
software due to a drift effect. This drift effect could be due to the camera moving to a 
new spot on the slide with each time point, however focus hold was used so that should 
not be occurring. Another factor could be due to photobleaching of the FAM dye, which 
we have observed with FCS, where we see the fluorescent counts decrease due to 
quenching of fluorescein as oligomers dissociate. To fix this problem we could try a 
different fluorescent probe less susceptible to photobleaching.  Another cause for the drift 
could be that as oligomers dissociate and detach from the glass cover slip free oligomer 
in solution bind to re-establish the equilibrium; this could be prevented by adding extra 
washes after binding oligomers or blocking the surface. Unfortunately, until more 
experiments can be done where the drift effect is eliminated no conclusions can be made.  
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Figure 4.9: Problem with TIRF data analysis is that with each time point the slide moved 
slightly. A shows t=0, B shows t= 30 mins C is t= 6 hours. Red dots= oligomers bound 
on slide. Yellow circle is what is being measured.  
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Chapter 5: Conclusions and Future Work 
5.1 Conclusions 
Amyloid beta oligomers are widely considered to be the main toxic aggregating 
species leading to Alzheimer’s disease pathology. For therapeutics to be developed it is 
necessary to understand how this protein aggregates and dissociates. The focus of this 
thesis was therefore to understand Aβ oligomer induced dissociation by select small 
molecules from the Apex Screen 5040 compound library. The compounds studied had 
been previously determined to be potent dissociators but little was understood about the 
dissociation mechanism, as the technique used, ELISA, is unable to give such 
information.41-42  Using FCS, we have found that these select small molecules from the 
Apex Screen 5040 library are able to bind to preformed amyloid beta oligomers causing 
them to lose stability. Furthermore, our data suggests that there are two possible 
dissociation mechanisms: higher order cooperative dissociation and linear dissociation, 
Figure 5.1.  
Figure 5.1: Proposed mechanisms of Aβ dissociation. A) Linear dissociation B) High 
order cooperative dissociation.  
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When Aβ oligomers were incubated with DMSO, 2,5 DHBA, 2C9, 39H8 or 39A8 
oligomer size remained constant while the fraction of oligomers in solution decreased. 
These results line up with a high order corporative dissociation model where oligomer 
immediately converts into monomers. On the other hand, when Aβ oligomers were 
incubated in urea, or Gdn HCl both oligomer fraction and size decreased, lining up with a 
linear dissociation model. It is obvious that a cooperative mechanism is more desirable 
for therapeutics as oligomer directly dissociates into monomer whereas in the linear 
mechanism toxic oligomer intermediates are formed. Furthermore, our data suggests that 
Aβ oligomer dissociation is dependent on dissociator concentration for both corporative 
and linear dissociators. However, more experiments are needed to fully understand the 
concentration dependency as this will provide insight into dissociation kinetics.  
While our data supports these proposed mechanisms when we consider the 
assembly pathway mentioned in section 1.4 these models do not make physical sense. To 
form oligomer, Aβ (1-42) firsts forms paranuclei; which are pentamers or hexamers. 
Then these paranuclei self- assemble to form large oligomers, as seen in Figure 5.2 A. 
Therefore, we hypothesize that the oligomers are all dissociating under one set pathway 
rather than there being two separate pathways. However, it appears to occur at different 
time scales based on dissociators used.  The mechanism is shown in Figure 5.2 B, where 
the first paranuclei unit is very hard to pull off from the large oligomer, but once that 
happens, the rest of the oligomer dissociates very fast. The fact that the dissociation 
occurs rapidly after the first hexamer falls off could prevent the size change from being 
observed by FCS. Although we can observe the size change in protein denaturants such 
as urea and Gdn HCl. This could be due to the fact these denaturants dissociate peptides 
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by weakening hydrophobic interactions and exposing hydrophobic residues; thereby 
allowing us to observe the size change as the rate of dissociation is slower. In order to 
validate this dissociation model more studies are needed.  One attempt to investigate this 
theory was the development of the TIRF method and concentration dependency studies.  
Figure 5.2 Proposed mechanism of Aβ oligomer assembly (A) and disassembly (B). 
While our NUNC coating experiments result did not match the expected result 
according to the Wennmalm paper, our results still point to oligomer binding to sample 
chamber as causing the issues of decreased fluorescence intensity and concentration 
rather than dye photobleaching. Interestingly our PEG coated oligomers do not seem to 
bind to the glass slide but do bind to the NUNC chamber. While experiments can be done 
on the glass slide, more experiments are needed to prove our hypothesis of PEG limiting 
Aβ adsorption to glass but not to the plastic NUNC due to increased surface area.   
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5.2 Future Work  
5.2.1 Sample adsorption experiments 
As mentioned previously our experiments were not able to completely fix the 
sample binding issue in the NUNC chamber. The first experiment needed, would be to 
prove that using PEG is why oligomers do not stick to glass, therefore Aβ oligomers 
could be prepared with and without PEG to verify this theory. Furthermore, to fix the 
deviation seen in concentration of the 30nM Aβ the confocal volume should be calibrated 
with both a high and low concentration of R110, which would also help verify the 
concentration does not change for 30nM Aβ on glass. Second would be to use a higher 
concentration and/or blocking time of PLL-PEG to try to stop binding in NUNC so that 
they can be used for future experiments. Furthermore, we could try to use BSA instead of 
PEG as the PEG molecules tested did not improve oligomer adsorption to the NUNC.   
5.2.2 TIRF 
As FCS primarily informs us about populations of oligomers, there would be 
benefits to examining the individual behavior of oligomers. TIRF would allow for the 
dissociation statistics across many individual oligomers within the same sample to be 
analyzed. TIRF would also allow the monitoring of oligomer dissociation at significantly 
faster time scales (millisecond vs minutes) to better understand if mechanistic differences 
exist (linear and higher order dissociation). However, the drift effect must be avoided 
before this technique can be used. If using a different fluorophore or extra wash steps do 
not eliminate the drift, then the results will have to be integrated manually. This will 
allow for dose-response curves on the individual oligomers to be examined. 16, 61 TIRF 
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would also allow for the examination of Aβ at physiological conditions (150 mM NaCl, 
and 37°C) to see if the mechanism or kinetics of dissociation change. We hypothesize 
that salt and higher temperature would increase, the oligomer dissociation rate. Because 
the goal is to provide insight into developing therapeutics for AD, knowing how the 
conditions present in the human body effect the mechanism or kinetics of dissociation 
would be valuable. TIRF would also enable the examination of the temperature 
dependence on dissociation kinetics. A major advantage of the TIRF method, if 
successful, would be the ability to extend this work in the future to the examination of 
other amyloid systems, such as tau or amylin. 
5.2.3 Complementary AFM studies 
Atomic force microscopy (AFM) studies which monitors Aβ oligomer size and 
concentration during small molecule induced dissociation is necessary to complement the 
FCS data of oligomer dissociation. AFM is capable of characterizing size and shape of 
differently sized protein aggregates at similar concentrations used for FCS. AFM does 
not require fluorescent labels; therefore, AFM studies would also allow us to examine if 
the fluorescein label on Aβ alters the dissociation kinetics. Similarly, the presence or lack 
of PEG during oligomer formation can also be examined by AFM to determine if PEG 
alters dissociation. Furthermore, AFM time course studies with the two different types of 
dissociators, cooperative vs linear, would help to determine if there are two different 
mechanisms of oligomer dissociation as observed by FCS.  
Preliminary work with AFM was performed on FAM labeled Aβ (1-42) oligomers 
deposited on mica, as outline in Appendix 3. The image obtained is shown in Figure 5.3 
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below and the oligomer size agreed with the FCS result. This result shows that AFM is a 
promising technique to monitor Aβ oligomer size during dissociation.  
Figure 5.3 AFM image of 1:4 FAM: WT Aβ (1-42) on mica. 
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APPENDICES 
Appendix A. Wennmalm’s results for Aβ adsorption onto glass surfaces33 
As mentioned in Ch. 3, Wennmalm, et.al, found that Aβ adsorbed onto the glass 
coverslip resulting in inaccurate measurements. Their results show that when 10-30 nM 
of Aβ was on untreated glass coverslips the fluorescence intensity decreased 95% in 5 
minutes. Furthermore using 30 s scans they saw a continuous increase in the diffusion 
coefficient. Taken together these results indicate Aβ absorption onto the glass. They were 
able to limit adsorption by pretreating the glass coverslips with poly-L-lysine-
polyethylene glycol (PLL-PEG), as shown in Figure A1. Their experiments were used as 
the basis of our coating studies.  
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Figure A1. Wennmalm showed that the fluorescence decrease was caused by oligomers 
absorbing to the sample holder and this can be avoided by coating the surface with poly-
l-lysine PEG. Reprinted from reference: Wennmalm, S.; Chmyrov, V.; Widengren, J.; 
Tjernberg, L., Highly Sensitive FRET-FCS Detects Amyloid beta-Peptide Oligomers in 
Solution at Physiological Concentrations. Anal Chem 2015, 87 (23), 11700-5. 
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Appendix B. Properties of Fluorescent dyes 
Fluorescein R110 Alexa 
488 
Atto 488 Hilyte Fluor 
488 
Abs / 
Em 
(nm) 
490 / 525 498 / 520 490 / 525 504 / 521 502 / 527 
D 
(μm2/s) 
425 440 430 400 430 
Table B1: Fluorescent dye properties. 44 
Figure B2:  Structures of fluorescent dyes. 
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Appendix C. Sample preparation for AFM studies 62-64 
9.9mm diameter mica discs were immobilized on 12mm metal specimen discs 
with double sided tape. Then double-sided tape was used to cleave the surface before 20 
μl of FAM- labeled Aβ oligomer, see Ch.2 for protocol, was deposited on the surface and 
incubated for 3 minutes. The surface was then rinsed with 0.2μm filtered DI water and 
gently dried with filtered nitrogen gas. Once the sample was loaded onto the AFM a scan 
rate of 1-2 Hz, with a drive amplitude 20-100mV, and set point 1-1.5 V were used to 
obtain images.   
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